The purpose of this study was to determine the optimum conditions for labeling genistein compounds with technetium-99m ( 99m Tc) radionuclides and the percentage of purity obtained in accordance with the requirements of the United State Pharmacopeia. The method used is optimization of several parameters including pH, SnCl 2 .2H 2 O as reducing agents, genistein concentration, and incubation time. The results showed that the optimum conditions for labeling 99m Tc-Genistein were obtained under conditions of pH 8, the amount of SnCl 2 .2H 2 O reducing agents was 30 µg, 0.5 mg genistein, and in 10 min. The optimization of this condition resulted in radiochemical purity in the labeling of 99m Tc-Genistein compounds at 95.43% ± 0.85%. The radiochemical purity of the labeling of 99m Tc-Genistein compounds has met the requirements of the United State Pharmacopeia as a compound marked for diagnosis of more than 90%.
INTRODUCTION
Cancer is the main disease that causes the biggest death in the world and caused deaths of around 8.2 million in 2012. The biggest cause of cancer deaths every year is caused by lung cancer, breast cancer, liver cancer, stomach cancer, and colorectal cancer. [1] In Indonesia, about 65% of people with breast cancer come to the doctor at an advanced stage; this indicates the patient is late to detect breast cancer. [2] Radiopharmaceuticals are compounds containing radioactive elements used for diagnostic purposes and therapeutic treatments for human diseases. Radiopharmaceuticals currently used are more than 95% more for diagnostic purposes and about 5% are used for therapeutic treatment. The application of the use of a compound labeled Technetium-99m ( 99m Tc) in nuclear medicine is very dominant, which is more than 80%. [3] 99m Tc for diagnostic purposes because it can emit pure gamma rays (140.5 keV) and has a short half-life time of around 6 h. Short half-life time is expected how the radiation emitted by 99m Tc can be used up immediately after the diagnosis process is complete so that the impact of radionuclide exposure can be minimized. [4] The main requirement of radionuclides and ligands for the diagnosis of cancer is that they can bind to the receptors to form complex compounds. One of the ligands that can be used is genistein. Genistein is an isoflavone compound that has pharmacological effects as anticancer and is able to bind to estrogen receptors with the nature of the selective estrogen receptor modulators. [5] TcO 4 -as much as 500 µL, then, the volume of the vial was equated with the addition of NaCl physiological solution to 2 mL and incubated for 30 min. The solution was formed, then dropped on the KLT SGF-254 and ITLC-SG plates to determine the purity of the 99m Tc-Genistein complex. [6] 
MATERIALS AND METHODS

Optimization of pH
Optimization of concentration genistein
The determination of optimum genistein concentrations used nine variations in genistein: 1; 2; 3; 4; 5; 6; 7; 7.5; and 10 mg/mL. Each solution was added with a solution of SnCl 2 .2H 2 O, and also added 99m TcO 4 -as much as 500 µL. After that, NaCl physiological solution was added to 2 mL and incubated for 30 min. Checking the purity of 99m Tc-Genistein complexes was done by dripping each solution on the KLT SGF-254 and ITLC-SG plates. Tc-Genistein complexes was done by dripping each solution on the KLT SGF-254 and ITLC-SG plates. [6] The purity percentage of 99m Tc-genistein compounds
Optimization of incubation time
The purity of the compound marked 99m
Tc-Genistein was determined using the TLC method which was then analyzed using SCA. The stationary phase used is the KLT SGF-254 and ITLC-SG plates. For the mobile phase, two solvents are used, namely C 1 solution consisting of ethanol: water: ammonia (2: 5: 1) and NaCl physiological solution. [7] The purity percentage of a compound labeled 99m 
RESULTS
Testing of optimum pH conditions
The pH factor is important in the stability of compounds marked and can affect the reduction power of the reducing agent used, namely SnCl 2 .2H 2 O. [5] The results for pH optimization testing and radiochemical purity of 99m Tc-genistein labeled compounds are shown in Table 1 and Figure 1 .
Test for optimum concentration of SnCl 2 .2H 2 O
SnCl 2 is reducing agent when in the form of Sn 2+ Sn 2+ is often used to reduce the level of reduction in medium with a low level of toxicity. [9] The results for the optimization of SnCl 2 .2H 2 O solutions and radiochemical purity of 99mTcgenistein labeled compounds are shown in Table 2 and Figure 2 .
Optimum concentration of genistein
Determination of the third parameter is the concentration of genistein solution, the concentration used is 1; 2; 3; 4; 5; 6; 7; 7.5; and 10 mg/mL. Ligands used to make radiopharmaceutical kits, should have a purity of 99% for other marked compounds derived from ligand impurities. [9, 10] The result for optimization concentration of genestein and radiochemical purity of 99m Tc-genistein labeled compounds are shown in Table 3 and Figure 3 . 
DISCUSSIONS
99m Tc radionuclides can form complex compounds with other elements into radiopharmaceutical preparations. The radiopharmaceutical preparation can be used for diagnosis. After being given to patients, radiopharmaceutical preparations can localize certain organs so that imaging can be carried out in the body based on cell function and physiology. [4] Tc can bind to the ligand to form a complex bond that has an electron donor group. The structure of genestein can be seen in Figure 5 . [6] The purity test of a 99m Tc-Genistein compound can be analyzed by the TLC method. The stationary phase used is thin-layer chromatography TLC SG F254 with the mobile phase of physiological NaCl solution to separate the form of 99m TcO 4 -, 99m TcO 4 -impurity will move toward the peak while 99m Tc-Genistein will remain at the bottling point and ITLC-SG stationary phase with C 1 mobile phase to separate 99m TcO 2 . The 99m TcO 2 impurity will remain at the bottling point, and 99m Tc-Genistein will move towards the peak. [11] The results at pH 8 showed that the optimum purity of 99m Tc-Genistein was 91.97% ± 1.43% with impurity of 99m TcO 4 -impurity, because at a higher pH, Sn (II) will be hydrolyzed to stano hydroxide which is no longer functioning as a reducing agent. Whereas in more acidic pH conditions, it will increase the amount of impurity 99m TcO 2 because the reducing agent SnCl 2 .2H 2 O will reduce more strongly in acidic conditions. [9, 10, 12] The results obtained on the optimum number of SnCl 2 .2H 2 TcO 2 colloid, so that the amount of impurity will be more 99m TcO 2 . [13] The optimization of genistein concentration was obtained at 10 mg/mL, but the solution produced was cloudy, as well as at 6, 7, and 7.5 mg/mL. Requirements for intravenous injection preparation, the solution produced must be clear. Therefore, the optimum concentration used was a concentration of 5 mg/mL, with a purity of 92.19% ± 1.86%.
The incubation time is strongly related to the preparation of a radiopharmaceutical preparation to be used. This is related to the effectiveness of the half-life of radionuclide used, and the purpose of therapy or diagnosis. The incubation time obtained is ideal for the application of 10 min. In the next minute, there was a relatively low decrease in purity and was not significant. The optimization of incubation time of 99m Tc-Genistein was obtained 10 min with optimum purity of 99m Tc-Genistein, which was 95.43% ± 0.85% with impurity of 99m TcO 2 0.57% ± 0.14% and impurity 99m TcO 4 -4.00% ± 0.72%.
CONCLUSIONS
The optimum condition for marking 99m Tc-Genistein produced radiochemical purity of 95.43% ± 0.85%. This fulfills the radiochemical purity requirements set by the United State Pharmacopeia as marked compounds for diagnosis of more than 90%.
